Compare FirstEnergy Corp. (FE) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FirstEnergy Corp. vs Summit Therapeutics Inc — how do they compare? FirstEnergy Corp. trades at $45 (market cap $25.95B), while Summit Therapeutics Inc trades at $17.38 (market cap $13.71B). The key difference: FirstEnergy Corp. is the larger of the two by market cap, and FirstEnergy Corp. pays a 4.15% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold FirstEnergy Corp. for 71 Days and Summit Therapeutics Inc for 16 Days on average.
| FE | SMMT | |
|---|---|---|
Market Cap | $25.95B | $13.71B |
Volume | 5,643,833 | 6,173,057 |
Sector | Utilities | Health |
52-Week High | $51.91 | $26.38 |
52-Week Low | $43.04 | $12.43 |
Typical Hold Time | 71 Days | 16 Days |
Enterprise Value | $54.87B | $13.04B |
Dividend Yield | 4.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FirstEnergy (FE) trades at $44.58, up 0.72% today, with a bullish technical signal but mixed earnings history. Revenue grew to $15.09B in 2025, with a net income margin of 6.86%, while valuation ratios like P/E of 23.84 and P/S of 1.63 suggest moderate pricing. Recent news highlights dividend declarations and a $36B Energize365 investment plan, supporting long-term growth amid rising data-center demand.
Outlook is positive with a consensus price target of $52.80, implying 18% upside, but risks include high debt levels and volatile cash flows. Analyst sentiment is mixed with 43% buy ratings, while institutional ownership trends show recent stake increases, indicating cautious optimism for steady utility returns.
Summit Therapeutics (SMMT) trades at $17.95, up 3.7% with strong technical momentum and bullish analyst sentiment. The stock shows negative profitability metrics but benefits from AstraZeneca's $2 billion strategic investment and clinical collaborations. Recent news highlights positive clinical trial results for ivonescimab, driving investor optimism despite current financial losses.
The outlook remains speculative with significant upside potential based on analyst consensus targets averaging $29.33, though high valuation multiples and negative cash flows present substantial risk. Success of clinical trials and partnership execution will determine long-term value creation for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About FirstEnergy Corp.
FirstEnergy is one of the largest investor-owned utilities in the United States with 10 regulated distribution companies across six mid-Atlantic and Midwestern states. FirstEnergy also owns and operates one of the nation's largest electric transmission systems with 24,000 miles of lines.
Read more on FE →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
